Antibiotic Resistant Strain, Helicobacter Pylori Infection
Conditions
Brief summary
The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.
Detailed description
Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant. Participants who did not have point mutations related to clarithromycin resistance and/or had clinically insignificant point mutations were treated with PAC (proton pump inhibitor, amoxicillin, clarithromycin) for 7 days, while participants with clinically significant point mutations were treated with PAM (proton pump inhibitor, amoxicillin, metronidazole) for 7 days. H. pylori eradication rates were compared between the two groups.
Interventions
DRUGproton pump inhibitor, amoxicillin, clarithromycin
non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
DRUGproton pump inhibitor, amoxicillin, metronidazole
clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
Sponsors
Kangdong Sacred Heart Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Helicobacter pylori infection
Exclusion criteria
* H. pylori eradication therapy within 1 year, * antibiotics within 4 weeks, * surgery for gastric cancer * malignant tumors other than gastric cancer * end-stage renal disease * liver cirrhosis, * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Helicobacter pylori eradication rate | 2 year | Number of participant with successful Helicobacter pylori eradication |
Outcome results
None listed